Year All2024202320222021202020192018201720162015201420132012201120102007 08.07.18 Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update -- PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 -- -- Phase 1 trial of SNDX-6352 in chronic graft versus host disease expected to commence by the end of the year -- -- Company to host conference call today at 4:30 p.m. Read More 07.31.18 Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 WALTHAM, Mass. , July 31, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2018 financial Read More 05.30.18 Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration WALTHAM, Mass. and SAN FRANCISCO , May 30, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) today announced a non-exclusive, clinical Read More 05.30.18 Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , May 30, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in two Read More 05.17.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) - Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation of PD-(L)1 refractory NSCLC patients with high levels of peripheral blood monocytes; 29% ORR and 5.4 months PFS observed in subpopulation - - Potential registration pathway identified in NSCLC; next trial Read More 05.08.18 Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update -- PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 -- -- ENCORE 601 data from PD-(L)1 refractory NSCLC and melanoma cohorts and first stage MSS-CRC cohort to be presented at ASCO -- -- Company to host conference call today at Read More 05.01.18 Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018 WALTHAM, Mass. , May 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2018 financial Read More 04.25.18 Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting WALTHAM, Mass. , April 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced five poster presentations at the upcoming American Read More 04.13.18 Syndax to Present at the 2018 American Association for Cancer Research Annual Meeting WALTHAM, Mass. , April 13, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced twelve oral and poster presentations at the upcoming Read More 03.05.18 Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update - Phase 2 ENCORE 601 PD-(L)1 refractory melanoma cohort data and melanoma registration strategy disclosure forthcoming in 2Q18 -- ENCORE 601 PD-(L)1 refractory NSCLC cohort data expected 2Q18 -- Initial data on MSS-CRC cohort of ENCORE 601 to drive decision on advancement into second stage expected in 2Q18 -- Company to host conference call today at 4:30 p.m. ET - Read More 03.05.18 Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , March 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 02.26.18 Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018 WALTHAM, Mass. , Feb. 26, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2017 financial Read More
08.07.18 Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update -- PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 -- -- Phase 1 trial of SNDX-6352 in chronic graft versus host disease expected to commence by the end of the year -- -- Company to host conference call today at 4:30 p.m. Read More
07.31.18 Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 WALTHAM, Mass. , July 31, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2018 financial Read More
05.30.18 Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration WALTHAM, Mass. and SAN FRANCISCO , May 30, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) today announced a non-exclusive, clinical Read More
05.30.18 Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , May 30, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in two Read More
05.17.18 Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) - Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation of PD-(L)1 refractory NSCLC patients with high levels of peripheral blood monocytes; 29% ORR and 5.4 months PFS observed in subpopulation - - Potential registration pathway identified in NSCLC; next trial Read More
05.08.18 Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update -- PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 -- -- ENCORE 601 data from PD-(L)1 refractory NSCLC and melanoma cohorts and first stage MSS-CRC cohort to be presented at ASCO -- -- Company to host conference call today at Read More
05.01.18 Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018 WALTHAM, Mass. , May 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2018 financial Read More
04.25.18 Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting WALTHAM, Mass. , April 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced five poster presentations at the upcoming American Read More
04.13.18 Syndax to Present at the 2018 American Association for Cancer Research Annual Meeting WALTHAM, Mass. , April 13, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced twelve oral and poster presentations at the upcoming Read More
03.05.18 Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update - Phase 2 ENCORE 601 PD-(L)1 refractory melanoma cohort data and melanoma registration strategy disclosure forthcoming in 2Q18 -- ENCORE 601 PD-(L)1 refractory NSCLC cohort data expected 2Q18 -- Initial data on MSS-CRC cohort of ENCORE 601 to drive decision on advancement into second stage expected in 2Q18 -- Company to host conference call today at 4:30 p.m. ET - Read More
03.05.18 Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , March 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
02.26.18 Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018 WALTHAM, Mass. , Feb. 26, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2017 financial Read More